The study assessed whether six MAPT haplotype-tagging polymorphisms (rs1467967, rs242557, rs3785883, rs2471738, del-In9, and rs7521) and MAPT haplotypes are associated with AD pathology, as measured by cerebrospinal fluid (CSF) AD biomarkers amyloid β<sub>1-42</sub> (Aβ<sub>1-42</sub> ), total tau (t-tau), tau phosphorylated at epitopes 181 (p-tau<sub>181</sub> ), 199 (p-tau<sub>199</sub> ), and 231 (p-tau<sub>231</sub> ), and visinin-like protein 1 (VILIP-1).